Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31042566 | 0.87 | MAPT (0.54) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15829329 | 0.87 | MAPT (0.49) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12244969 | 0.86 | MAPT (0.56) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4070406 | 0.85 | CFTR (0.62) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL690558 | 0.84 | NR1H4 (0.53) | MAPTKDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL8260775 | 0.84 | MAPT (0.49) | MAPTSMN1; SMN2NPSR1NR1I2HTT | |
| SCHEMBL23645185 | 0.84 | CFTR (0.51) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4395058 | 0.83 | EGFR (0.48) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13136420 | 0.83 | KDM4E (0.50) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9187252 | 0.83 | NR1H4 (0.52) | MAPTKDM4EALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| US-7776898-B2 | high binding affinity, high selectivity, bioavailability; analgesics; 1-{3-[4-(tert-Butyl)phenyl]-(1,2,4-triazol-4-yl)}-3-methoxybenzene | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776898-B2 | high binding affinity, high selectivity, bioavailability; analgesics; 1-{3-[4-(tert-Butyl)phenyl]-(1,2,4-triazol-4-yl)}-3-methoxybenzene | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776898-B2 | high binding affinity, high selectivity, bioavailability; analgesics; 1-{3-[4-(tert-Butyl)phenyl]-(1,2,4-triazol-4-yl)}-3-methoxybenzene | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2010-08-17 | — | — | US | disclosed |
| US-7671080-B2 | 1-benzylindole-2-carboxamide derivatives | N.V. ORGANON (NL) | 2010-03-02 | — | — | US | disclosed |
| US-7531560-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531560-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531560-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | N.V. ORGANON (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1485088-B1 | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | UNIV MISSOURI (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7294720-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294720-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294720-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
| US-20060128776-A1 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2006-06-15 | — | — | US | disclosed |
| US-7045520-B2 | Opioid receptor active compounds | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060100204-A1 | Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| EP-1485088-A1 | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030225072-A1 | Opioid receptor active compounds | CURATORS OF THE UNIVERSITY OF MISSOURI, THE | 2003-12-04 | — | — | US | disclosed |
| WO-2003066050-A1 | OPIOID RECEPTOR ACTIVE 4-(3-HYDROXYPHENYL) OR 4-(3-ALKOXYPHENYL)-1,2,4-TRIAZOLE COMPOUNDS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225072-A1 | Opioid receptor active compounds | OPRL1, OPRM1, OPRK1 | MAPT 3834/4885KDM4E 2257/4885ALDH1A1 582/4885 |
| US-20060100204-A1 | Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. | NFKBIA, CHUK, IL1B | MAPT 2580/4885KDM4E 344/4885ALDH1A1 974/4885 |
| US-20060128776-A1 | Opioid receptor active compounds | OPRL1, OPRM1, OPRK1 | MAPT 3543/4885KDM4E 2873/4885ALDH1A1 679/4885 |
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | CNR2, CNR1, HTR2C | MAPT 1371/4885KDM4E 504/4885ALDH1A1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.